SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📊Dashboards🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

Gut-derived butyrate reprograms microglia for amyloid clearance via HDAC2 inhibition

Target: HDAC2 Composite Score: 0.000 Price: $0.50 Citation Quality: Pending Alzheimer's disease Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
5
Citations
1
Debates
5
Supporting
1
Opposing
Quality Report Card click to collapse
F
Composite: 0.000
Top 50% of 1512 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B+ Mech. Plausibility 15% 0.78 Top 23%
B+ Evidence Strength 15% 0.72 Top 19%
B Novelty 12% 0.68 Top 54%
B+ Feasibility 12% 0.78 Top 25%
F Impact 12% 0.00 Top 50%
F Druggability 10% 0.00 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
F Reproducibility 5% 0.00 Top 50%
Evidence
5 supporting | 1 opposing
Citation quality: 40%
Debates
1 session A+
Avg quality: 0.95
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

Gut-Brain Axis Therapeutics for AD

Can gut-brain axis modulation prevent or slow Alzheimer's disease pathology?

→ View full analysis & debate transcript

Description

Specific butyrate-producing gut bacteria (e.g., Faecalibacterium, Roseburia) generate systemic butyrate that crosses the blood-brain barrier and inhibits hippocampal microglial HDAC2, leading to hyperacetylation of transcription factors that upregulate TREM2-independent phagocytic pathways. This enhances microglial amyloid-beta uptake and lysosomal degradation while suppressing NLRP3 inflammasome activation. Testable prediction: Germ-free AD mice colonized with butyrate-producing bacteria or treated with sodium butyrate will show reduced amyloid plaque burden, increased microglial amyloid phagocytosis rates ex vivo, and decreased IL-1β and caspase-1 levels, compared to controls.

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.78 (15%) Evidence 0.72 (15%) Novelty 0.68 (12%) Feasibility 0.78 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.000 composite
6 citations 6 with PMID 5 medium Validation: 40% 5 supporting / 1 opposing
✓ For (5)
5
No opposing evidence
(1) Against ✗
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
1
2
MECH 3CLIN 1GENE 2EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
TREM2 drives microglia response to amyloid-β via S…SupportingGENECell MEDIUM2022-PMID:36306735-
Human and mouse single-nucleus transcriptomics rev…SupportingMECHNat Med MEDIUM2020-PMID:31932797-
TREM2, microglia, and Alzheimer's disease.SupportingMECHMech Ageing Dev MEDIUM2021-PMID:33516818-
TREM2 Maintains Microglial Metabolic Fitness in Al…SupportingGENECell MEDIUM2017-PMID:28802038-
The TREM2-APOE Pathway Drives the Transcriptional …SupportingMECHImmunity MEDIUM2017-PMID:28930663-
CNS effects of sodium butyrate require supraphysio…OpposingCLIN- STRONG--PMID:33785315-
Legacy Card View — expandable citation cards

✓ Supporting Evidence 5

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. MEDIUM
Cell · 2022 · PMID:36306735
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses… MEDIUM▼
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.
Nat Med · 2020 · PMID:31932797
TREM2, microglia, and Alzheimer's disease. MEDIUM
Mech Ageing Dev · 2021 · PMID:33516818
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. MEDIUM
Cell · 2017 · PMID:28802038
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Di… MEDIUM▼
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Immunity · 2017 · PMID:28930663

✗ Opposing Evidence 1

CNS effects of sodium butyrate require supraphysiological doses administered systemically (≥300 mg/kg in roden… STRONG▼
CNS effects of sodium butyrate require supraphysiological doses administered systemically (≥300 mg/kg in rodents) that gut-derived butyrate cannot achieve in CSF; colonocyte beta-oxidation and hepatic first-pass metabolism rapidly catabolize portal butyrate, leaving negligible concentrations to cross the BBB
PMID:33785315
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-06 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Based on the literature provided, I'll generate novel therapeutic hypotheses targeting the gut-brain axis for Alzheimer's disease prevention and treatment:

Hypothesis 1: Microglial Priming Reset via Short-Chain Fatty Acid Epigenetic Modulation

Description: Specific probiotic strains producing high levels of butyrate and propionate can epigenetically reprogram microglial cells from a primed inflammatory state to a neuroprotective phenotype, preventing amyloid-β-induced neuroinflammation. This involves histone deacetylase inhibition by SCFAs, leading to enhanced expression of anti-inflam

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

I'll provide a rigorous critique of each hypothesis based on the provided literature and scientific principles.

Hypothesis 1: Microglial Priming Reset via SCFA Epigenetic Modulation

Critical Weaknesses:

  • Oversimplified mechanistic assumption: The hypothesis assumes direct SCFA-mediated HDAC inhibition will predictably reprogram microglia, but PMID:33374235 shows that microglial responses are context-dependent and influenced by multiple factors beyond SCFAs.
  • Blood-brain barrier limitations: While SCFAs can cross the BBB, the concentrations reaching brain tissue may be insu

    • 🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

    I'll assess the practical feasibility of these gut-brain axis hypotheses for Alzheimer's disease, focusing on druggability, existing compounds, competitive landscape, and development timelines.

    OVERALL FEASIBILITY ASSESSMENT

    Most Viable Hypotheses: #4 (Gut Barrier Reconstruction) and #7 (Personalized Medicine) Least Viable: #2 (Vagal Tone Enhancement) and #5 (Engineered Probiotics)

    HYPOTHESIS 1: Microglial Priming Reset via SCFA Epigenetic Modulation

    Druggability Assessment: MODERATE

    • Target: HDAC2/3 inhibition is well-established (existing drugs: suberoylan

    ⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

    Price History

    No price history recorded yet

    7d Trend
    ↔
    Stable
    7d Momentum
    ▲ 0.0%
    Volatility
    Low
    0.0000
    Events (7d)
    0

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (6)

    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    TREM2, microglia, and Alzheimer's disease.
    Mech Ageing Dev (2021) · PMID:33516818
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet

    📙 Related Wiki Pages (0)

    No wiki pages linked to this hypothesis yet.

    ࢐ Browse all wiki pages

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    📊 Resource Economics & ROI

    Moderate Efficiency Resource Efficiency Score
    0.50
    32.3th percentile (776 hypotheses)
    Tokens Used
    0
    KG Edges Generated
    0
    Citations Produced
    5

    Cost Ratios

    Cost per KG Edge
    0.00 tokens
    Lower is better (baseline: 2000)
    Cost per Citation
    0.00 tokens
    Lower is better (baseline: 1000)
    Cost per Score Point
    0.00 tokens
    Tokens / composite_score

    Score Impact

    Efficiency Boost to Composite
    +0.050
    10% weight of efficiency score
    Adjusted Composite
    0.050

    How Economics Pricing Works

    Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

    High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

    Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

    Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

    Related Hypotheses

    Gut butyrate deficiency impairs microglial amyloid clearance via HDAC2-mediated epigenetic dysregulation
    Score: 0.000 | Alzheimer's disease
    HDAC2-Specific Repression of PU.1 Pioneer Factor Target Sites Suppresses the IL-33/ST2-Phagocytic Axis; HDAC2 Deletion Specifically Unmasks These Enhancers
    Score: 0.415 | neurodegeneration
    Closed-loop tFUS targeting of EC-II SST interneurons to prevent ACSL4-mediated ferroptotic priming in disease-associated microglia
    Score: 0.000 | Alzheimer's disease
    XOR+ stress-responsive astrocytes represent a novel AD-associated cell state linking oxidative stress to regional vulnerability
    Score: 0.000 | Alzheimer's disease
    Convergent NF-κB enhancers across diverse priming stimuli share therapeutic vulnerability to BET inhibitors
    Score: 0.000 | Alzheimer's disease

    Estimated Development

    Estimated Cost
    $0
    Timeline
    0 months

    🧪 Falsifiable Predictions

    No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

    Knowledge Subgraph (0 edges)

    No knowledge graph edges recorded

    3D Protein Structure

    🧬 HDAC2 — PDB 3MAX Click to expand 3D viewer

    Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

    Source Analysis

    Gut-Brain Axis Therapeutics for AD

    neurodegeneration | 2026-04-01 | completed

    Community Feedback

    0 0 upvotes · 0 downvotes
    💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

    No comments yet. Be the first to comment!

    View all feedback (JSON)

    ← Back to Exchange | Dashboard